<DOC>
	<DOCNO>NCT01646671</DOCNO>
	<brief_summary>This study assess safety , tolerability , efficacy LCZ696 severe hypertensive Japanese patient</brief_summary>
	<brief_title>Safety Tolerability Efficacy LCZ696 Japanese Severe Hypertensive Patients</brief_title>
	<detailed_description>Summaries treatment-emergent adverse event , serious adverse event death provide follow actual treatment regimen ( actual treatment patient receive ) addition patient : LCZ696 200mg , 400mg , 400mg+other hypertensive medication . Summaries others provide follow treatment regimen ( determine maximal treatment patient receive ) addition patient : LCZ696 200mg , 400mg , 400mg+other hypertensive medication .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Satisfy office msSBP ≥180 mmHg office msDBP ≥110 mmHg baseline Patients show msSBP ≥220 mmHg and/or msDBP ≥120 mmHg History angioedema , drugrelated otherwise , report patient Patients unwilling able discontinue safely use current antihypertensive medication study , require protocol . Patients significant cardiovascular comorbidities Patients previously enter LCZ696 study randomize enrolled active drug treatment epoch . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hypertension , Severe , LCZ696</keyword>
</DOC>